US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Xtrackers Nifty 500 India ETF

23.00

+0.11000.48%

Volume:104

Turnover:2K

Market Cap:4.60M

PE:- -

High:23.00

Open:22.89

Low:23.00

Close:22.89

52wk High:27.40

52wk Low:20.52

Shares:200.00K

Float Shares:200.00K

Volume Ratio:0.53

T/O Rate:0.05%

Dividend:0.08

Dividend Rate:0.34%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress

Press Release: Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

Press Release: Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts

Press Release: Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update

Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates

Press Release: ArriVent BioPharma Reports Second Quarter 2026 Financial Results

NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma

Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates

TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Press Release: Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update

Traders Reveal Reserve Bank of India Selling Dollars in FX Market to Prop Up Rupee

Press Release: Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

AC Immune receives fast track designation, clearance for ACI-7104 IND

Press Release: Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update

Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development

Press Release: Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates

Press Release: Olema Oncology Reports Second Quarter 2026 Financial and Operating Results

NeOnc Heads into a High-Stakes Week as Highly Anticipated NEO100 Phase 2a Data Readout Nears

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/IND/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IND","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND\",,,,,undefined,":{"symbol":"IND","market":"US","secType":"STK","nameCN":"Xtrackers Nifty 500 India ETF","latestPrice":22.995,"timestamp":1787342400000,"preClose":22.885,"halted":0,"volume":104,"delay":0,"changeRate":0.004806641905178039,"floatShares":200001,"shares":200001,"eps":0,"marketStatus":"Pre-Mkt","change":0.11,"latestTime":"08-24 09:07:25 EDT","open":22.885,"high":22.995,"low":22.995,"amount":2400,"amplitude":0,"askPrice":34.49,"askSize":101,"bidPrice":11.5,"bidSize":101,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787578200000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":22.995,"sharesOutstanding":200001,"nav":23.031,"aum":4606217.85,"dividendRate":0.003418,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":22.885,"preClose":22.995,"latestTime":"16:10 EDT","volume":8,"amount":183.96,"timestamp":1787343004209,"change":-0.11,"changeRate":-0.004784,"amplitude":0},"volumeRatio":0.5306123531861945},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND\",,,,,undefined,":{"symbol":"IND","floatShares":200001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.5306123531861945,"shares":200001,"dividePrice":0.0786,"high":22.995,"amplitude":0,"preClose":22.885,"low":22.995,"week52Low":20.515,"pbRate":"--","week52High":27.4,"institutionHeld":0,"latestPrice":22.995,"eps":0,"divideRate":0.003418,"volume":104,"delay":0,"ttmEps":0,"open":22.885,"prevYearClose":24.78,"prevWeekClose":22.995,"prevMonthClose":22.885,"prevQuarterClose":22.88,"fiveDayClose":23.09,"twentyDayClose":22.155,"sixtyDayClose":22.475},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IND\",params:#limit:5,,,undefined,":[{"date":"2026-06-18","symbol":"IND","amount":0.07775,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-18","defaultRemindTime":1781789400000,"name":"Xtrackers Nifty 500 India ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-18","currency":"USD","dateTimestamp":1781755200000,"payDate":"2026-06-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IND\",market:\"US\",,,undefined,":[{"executeDate":"2026-06-18","recordDate":"2026-06-18","paymentDate":"2026-06-26","value":0.07775,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IND\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IND\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659195237","title":"Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2659195237","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659195237?lang=en_us&edition=fundamental","pubTime":"2026-08-14 05:02","pubTimestamp":1786654920,"startTime":"0","endTime":"0","summary":"Reported a reduction in muscle fat fraction by MRI along with increased total effort in all TRAILHEAD participants at month six, suggestive of muscle regenerationContinued favorable safety and tolerab","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3345007/0/en/satellos-reports-second-quarter-2026-financial-results-and-highlights-company-progress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HYLG","BK4139","PRGS","IDNA","BMED","IND","NVIB","BK4097","MEDX","MSLE","LU2065732104.USD","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162993","title":"Press Release: Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162993","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162993?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"-- Achieved Q2 2026 PEMGARDA  net product revenue of $14.3. million, representing 21% growth versus Q2 2025 net product revenue of. -- Completed rapid enrollment in VYD2311 DECLARATION clinical trial. expansion cohort and LIBERTY clinical trial, driven by strong subject. -- DECLARATION pivotal clinical trial enrollment is complete; the ongoing. study is approaching its planned analysis, and in lieu of a Q2 2026. quarterly earnings call, Invivyd plans to hold an investor call post. -- Strong balance sheet with Q2 2026 ending cash and cash equivalents of. $160.1 million anticipated to provide runway through DECLARATION pivotal. data readout and support potential commercial launch readiness for. 30, 2026, compared to $11.8 million in for the quarter ended June 30,-- In July 2026, Invivyd announced receipt of twelve months' advanced notice. of emergency use authorization  termination for PEMGARDA and that. the company is in dialogue with the U.S. Food and Drug Administration.  about approp","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4551","BK4535","BK4585","BK4539","IVVD","MEDX","NVIB","BK4568","GDOC","R","BNTX","IDNA","BK4022","HYLG","BK4548","IND","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659516286","title":"Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2659516286","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659516286?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:02","pubTimestamp":1786651320,"startTime":"0","endTime":"0","summary":"Eikon announced seven abstracts accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026 highlighting progress across Eikon’s oncology portfolio, including clinical ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3344893/0/en/eikon-therapeutics-reports-second-quarter-2026-financial-results-and-provides-clinical-updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0210528500.USD","BK4139","LU0053666078.USD","EIKN","BK4189","CNS","DMC","BK4135","IND","L","LU2487616109.SGD","BK4107","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659907724","title":"Press Release: Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2659907724","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659907724?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:05","pubTimestamp":1786565100,"startTime":"0","endTime":"0","summary":"Arm 3 with ultra-low dose gemcitabine sensitization) in the. registrational-intent Phase 2b study, across both US and European. -- Two presentations at the American Association for Cancer Research . Annual Meeting highlighted data showing the underlying molecular. mechanisms for potent synergies between ACR-368 and immune checkpoint. AP3. These findings support the potential for clinical combination. studies with antibody-drug conjugates  or ICIs.ACR-2316-- ACR-2316 advanced into the randomized dose expansion stage of the Phase. 1/2 study, supported by observed favorable safety profile and durable. antitumor activity. The expansion phase is evaluating 120 mg and 160 mg. doses, administered orally, once-daily  utilizing a 3d on / 4d off. -- Dose expansion phase will assess safety and activity in subjects with","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","BK4201","BK4139","EC","ACRV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659907259","title":"Press Release: Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659907259","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659907259?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:05","pubTimestamp":1786565100,"startTime":"0","endTime":"0","summary":"-- On track for September 2026 top-line results from Phase 2b clinical trial.  evaluating laromestrocel as a potential adjunct treatment for. hypoplastic left heart syndrome , a rare pediatric disease and. -- Longeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE. Healthspan competition based on published clinical trial results which. indicated laromestrocel increased 6-minute walk distance in patients with. -- Three new independent Directors join Longeveron's Board of Directors. laromestrocel as a potential adjunct therapy for HLHS are anticipated in. -- In May, the Company announced that the U.S. Food and Drug Administration.  held a Type C meeting in late March 2026 focused on the ELPIS II. Phase 2b clinical trial and upcoming data readout.-- Also in May, the Company announced that the independent Data Monitoring. Committee  completed its final prespecified data review for ELPIS II. Phase 2b clinical trial . The DMC performed a risk-benefit. assessment, indicated n","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","IND","BK4022","IDNA","EMA","MEDX","R","GDOC","HYLG","LGVN","BK4189","AD","NVIB","DMC","BK4081","BK4139","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659185590","title":"Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2659185590","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659185590?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:05","pubTimestamp":1786565100,"startTime":"0","endTime":"0","summary":"IND for ribupatide oral active with U.S. FDA, initiation of global Phase 3 obesity trials planned for the first half of 2027Ribupatide injection Phase 2b high-dose trial in obesity fully enrolled, dat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/12/3344078/0/en/kailera-reports-second-quarter-2026-financial-results-and-provides-business-updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JDOC","BBC","PSIL","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659074329","title":"Press Release: ArriVent BioPharma Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2659074329","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659074329?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:01","pubTimestamp":1786564860,"startTime":"0","endTime":"0","summary":"-- Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR. -- ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced. -- Dosing of first patient with ARR-002, a dual-targeting MUC16/NaPi2b. tetravalent ADC with initial focus in ovarian and endometrial cancers. -- Cash and investments of $373.1 million as of June 30, 2026 expected to. Ongoing pivotal Phase 3 study in frontline EGFR exon 20 insertion mutant. NSCLC supported by preclinical data for EGFR inhibitor firmonertinib. showcased high resolution crystal structure data at the 2026 American. Association for Cancer Research  Annual Meeting.Pipeline-- Initiated Phase 1b Dose Optimization of ADC lead ARR-217 .ArriVent has initiated Phase 1b dose optimization for ARR-217, a CDH17. targeted ADC, in patients with gastrointestinal malignancies in. -- Clinically advancing ARR-002 in ovarian and endometrial cancer. ArriVent. the clinic through a first-in-human study evaluating safety, dosing, and. early s","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","CRC","BK4080","ADC","NETL","AVBP","BK4231","BK4139","BK4213","LU0456854461.SGD","LU0266512127.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658086719","title":"NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma","url":"https://stock-news.laohu8.com/highlight/detail?id=2658086719","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658086719?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:00","pubTimestamp":1786536000,"startTime":"0","endTime":"0","summary":"Company to request a Type B meeting with the FDA to align on a registrational path in a setting with no approved targeted therapy — Study met its primary endpoint: six-month progression-free survival ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/12/3343608/0/en/neonc-technologies-reports-positive-topline-phase-2a-results-for-intranasal-neo100-in-recurrent-idh1-mutant-high-grade-glioma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","IND","BK4135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658908970","title":"Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658908970","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658908970?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:30","pubTimestamp":1786534200,"startTime":"0","endTime":"0","summary":"Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Advancing IND-enabling studies for potential first-in-class multi-specific, masked T cell ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/12/3343546/0/en/xilio-therapeutics-reports-second-quarter-2026-financial-results-and-provides-pipeline-and-business-updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","IND","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658089799","title":"TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2658089799","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658089799?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:00","pubTimestamp":1786532400,"startTime":"0","endTime":"0","summary":"First patient dosed in Phase 3 ALLOHA-2 study; topline readout expected mid-2028 Shared positive initial data from Cohort C of Phase 1 ALLOHA study, validating internal commercial-ready manufacturing ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/12/3343490/0/en/tscan-therapeutics-reports-second-quarter-2026-financial-results-and-provides-corporate-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EES","BK4139","BK4007","IDMO","IND","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658044979","title":"Press Release: Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2658044979","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658044979?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:00","pubTimestamp":1786532400,"startTime":"0","endTime":"0","summary":"-- Breakthrough results from V012 dialysis access Phase 3 study, where ATEV was observed to outperform AV fistula; supplemental Biologic License Application (sBLA) for dialysis access to be filed with","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAA","SPRE","AV","CTEV","BK4167","IND","BK4232","LABU","BK4215","BK4563","BK4022","BK4588","R","HUMA","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194634718","title":"Traders Reveal Reserve Bank of India Selling Dollars in FX Market to Prop Up Rupee","url":"https://stock-news.laohu8.com/highlight/detail?id=1194634718","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194634718?lang=en_us&edition=fundamental","pubTime":"2026-08-12 12:25","pubTimestamp":1786508739,"startTime":"0","endTime":"0","summary":"According to traders familiar with the matter, the Reserve Bank of India is selling US dollars in the onshore foreign exchange market to support the Indian rupee, as the currency faces pressure from...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCO","INDL","BK4523","BK4588","FLIBF","ASGM","INDA","IND","IMVP","SMIN","INDE","EPI","UUP","TAJX","XCEM","GIND","BK4585","NFTY","INDY","FLIN","UDN","NDIA","SCIN","PIN","IOPP","INQQ","GLIN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658451129","title":"Press Release: Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658451129","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658451129?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:53","pubTimestamp":1786481580,"startTime":"0","endTime":"0","summary":"and the OLE  trial to assess the totality of. available efficacy and safety data and to support an informed. determination of next steps for the ARD-101 program. In June 2026, the. Company terminated the HERO and the OLE trial and does not currently. intend to resume these trials as previously designed.-- In May 2026, the Company announced that the U.S. Food and Drug. Administration  placed a full clinical hold on its investigational. new drug application  for ARD-101, related to the Company's. previously announced voluntary pause. The clinical hold applies to all. previously ongoing clinical studies under the IND, including the Phase 3. HERO trial evaluating ARD-101 for the treatment of hyperphagia in. patients with Prader-Willi Syndrome  and the Phase 3 OLE trial.Second Quarter 2026 Financial Highlights-- Cash Position: As of June 30, 2026, Aardvark had cash, cash equivalents. and short-term investments of $73.9 million, compared to $91.2 million as. of March 31, 2026. Based on curre","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IDNA","NVIB","IND","MEDX","GDOC","HYLG","PWS","BMED","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658997637","title":"AC Immune receives fast track designation, clearance for ACI-7104 IND","url":"https://stock-news.laohu8.com/highlight/detail?id=2658997637","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658997637?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:41","pubTimestamp":1786448502,"startTime":"0","endTime":"0","summary":"AC Immune (ACIU) announced that it has received fast track designation and clearance of its investigational new drug, or IND, application from the ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ac-immune-receives-fast-track-designation-clearance-for-aci-7104-ind-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ac-immune-receives-fast-track-designation-clearance-for-aci-7104-ind-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IND","BK4113","ACI","BK4139","ACIU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658994051","title":"Press Release: Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2658994051","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658994051?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:00","pubTimestamp":1786446000,"startTime":"0","endTime":"0","summary":"at the 3rd International GBA1 Meeting 2026 in May 2026 in Phoenix, AZ.-- As of May 2026, all 16 participants enrolled in the Phase 1b,nine-month extension remained on study and had completed five. -- MDS-UPDRS scores remained stable and durable across the overall. study population after 150 days of treatment with rexaceract.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","BK4099","BK4218","BK4555","CSF","LU1169589451.USD","03160","BK4604","INN","GT","GANX","BK4588","BK4119","BK4585","BK4181","LU1169590202.USD","IND","BK4139","PD","TM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658952508","title":"Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2658952508","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658952508?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:20","pubTimestamp":1786393200,"startTime":"0","endTime":"0","summary":"Advancing a potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug specifically engineered for the treatment of inflammatory bowel disease (IBD) Enrollment of first patien","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/10/3342259/0/en/palisade-bio-reports-second-quarter-2026-financial-results-and-highlights-continued-advancement-of-pali-2108-into-phase-2-development.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CD","BK4116","GDOC","IE00B1BXHZ80.USD","PD","IBD","LU2237443895.HKD","CMC","BK4023","IE00BHPRN162.USD","MEDX","LU1169589451.USD","LU1363072403.SGD","LU2237443978.SGD","LU2746668974.SGD","PALI","LU0267386448.USD","IDNA","BK4139","BK4007","IND","LU0971096721.USD","LU1169590202.USD","LU0149725797.USD","IE00BFXG1179.USD","LU2237443622.USD","IE00BKVL7J92.USD","HYLG","NVIB","LU2237443382.USD","LU0170899867.USD","IE00BZ1G4Q59.USD","LU0882574139.USD","LU2237443465.HKD","LU2237443549.SGD","BK4127","LU2746668461.USD","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658959548","title":"Press Release: Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2658959548","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658959548?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:05","pubTimestamp":1786392300,"startTime":"0","endTime":"0","summary":"of the third quarter of 2026, including GLP toxicity. The Company remains. on track to submit an IND application in the fourth quarter of 2026 for. the global clinical program, and subject to regulatory clearance,-- Two Metagenomi scientific posters received Top Poster Awards at the 2026. International Society on Thrombosis and Haemostasias  Congress in. Paris, France, including one highlighting extensive non-human primate. preclinical data supporting MGX-001.MGX-001 - Large Gene Integration System for Protein Replacement via Gene Insertion-- The Company continues to evaluate disease indications which have the","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","IND","MGX","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658952506","title":"Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658952506","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658952506?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:05","pubTimestamp":1786392300,"startTime":"0","endTime":"0","summary":"One-year REMAIN-1 Midpoint Cohort data show Revita patients maintained up to 84% of prior GLP-1-induced weight loss versus 46% with sham in patients receiving complete duodenal ablations — the first r","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/10/3342215/0/en/fractyl-health-reports-second-quarter-2026-financial-results-and-business-updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTA","BK4082","GUTS","JDOC","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658995628","title":"Press Release: Olema Oncology Reports Second Quarter 2026 Financial and Operating Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2658995628","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658995628?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:01","pubTimestamp":1786392060,"startTime":"0","endTime":"0","summary":"-- Completed enrollment in the pivotal Phase 3 OPERA-01 trial; top-line data. -- Presented initial Phase 1 clinical data for OP-3136 at the 2026 ASCO. -- Announced a clinical trial collaboration and supply agreement with Bayer. to evaluate darolutamide in combination with OP-3136 in metastatic. -- Ended the second quarter with $461.1 million in cash, cash equivalents,palazestrant as a monotherapy in patients with second or third-line. estrogen receptor-positive (ER+), human epidermal growth factor receptor. -- Presented initial Phase 1 clinical data for OP-3136 as a monotherapy in. multiple solid tumor types and a trial-in-progress poster for the pivotal. Phase 3 OPERA-02 trial evaluating palazestrant in combination with. ribociclib in frontline ER+/HER2- MBC at the 2026 American Society of","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OLMA","MEDX","MBC","BK4086","GDOC","HYLG","IND","NVIB","OP.USD.HKCC","BK4139","IDNA","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658953571","title":"NeOnc Heads into a High-Stakes Week as Highly Anticipated NEO100 Phase 2a Data Readout Nears","url":"https://stock-news.laohu8.com/highlight/detail?id=2658953571","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658953571?lang=en_us&edition=fundamental","pubTime":"2026-08-10 22:34","pubTimestamp":1786372440,"startTime":"0","endTime":"0","summary":"Topline Results from Intranasal NEO100 in Recurrent IDH1-mutant High-grade Glioma could mark a Major Clinical Catalyst for NeOncDENVER, Aug.  10, 2026 (GLOBE NEWSWIRE) -- (247mnn.com) –NeOnc Technolog","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/10/3341958/0/en/neonc-heads-into-a-high-stakes-week-as-highly-anticipated-neo100-phase-2a-data-readout-nears.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4135","IND","CNS","BBB","NTHI"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}